5月13日,复宏汉霖早盘股价上涨7.74%,报36.90港元。公司4月底与Sandoz AG达成合作,授予其开发、生产及商业化HLX13(伊匹木单抗生物类似药)的权利。Sandoz将支付至多1.91亿美元,包括首付款和开发里程碑款。2024年,原研药伊匹木单抗全球销售额达28.73亿美元。天风证券认为,凭借Sandoz的商业化能力及复宏汉霖领先的临床进度,HLX13有望推动公司海外销售峰值进一步...
Source Link5月13日,复宏汉霖早盘股价上涨7.74%,报36.90港元。公司4月底与Sandoz AG达成合作,授予其开发、生产及商业化HLX13(伊匹木单抗生物类似药)的权利。Sandoz将支付至多1.91亿美元,包括首付款和开发里程碑款。2024年,原研药伊匹木单抗全球销售额达28.73亿美元。天风证券认为,凭借Sandoz的商业化能力及复宏汉霖领先的临床进度,HLX13有望推动公司海外销售峰值进一步...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.